Related Experiment Video
Updated: Apr 28, 2026
Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye
Published on: November 25, 2012
Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy
1Department of Ophthalmology, F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia 19104, USA.
Abstract:
Mutations in the beta subunit of the cGMP phosphodiesterase gene (beta PDE) can cause a recessively inherited retinal degeneration in several species, including mice, dogs and humans. We tested the possibility of altering the course of retinal degeneration in the rd mouse through subretinal injection of a recombinant replication-defective adenovirus that contains the murine cDNA for wild-type (beta PDE, Ad.CMV beta PDE. Subretinal injection of Ad.CMV beta PDE results in beta PDE transcripts and increased PDE activity and delays photoreceptor cell death by six weeks. The findings demonstrate cell rescue by in vivo gene transfer, thus supporting the feasibility of treating an inherited retinal degeneration by somatic gene therapy.
Insights
Gene therapy using Ad.CMV beta PDE successfully delayed photoreceptor cell death in rd mice. This study supports the potential of somatic gene therapy for treating inherited retinal degeneration.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- Recessive mutations in the beta subunit of the cGMP phosphodiesterase gene (beta PDE) are linked to inherited retinal degeneration in various species.
- This condition affects photoreceptor cells, leading to vision loss.
Purpose of the Study:
- To investigate the efficacy of in vivo gene transfer for treating inherited retinal degeneration.
- To determine if subretinal injection of a specific adenovirus vector can alter the course of retinal degeneration in the rd mouse model.
Main Methods:
- Subretinal injection of a recombinant replication-defective adenovirus (Ad.CMV beta PDE) carrying the wild-type murine beta PDE cDNA into rd mice.
- Analysis of beta PDE transcripts and phosphodiesterase (PDE) activity post-injection.
- Monitoring of photoreceptor cell death to assess the therapeutic effect.
Main Results:
- Successful expression of beta PDE transcripts and increased PDE activity in the treated retinas.
- A significant delay of six weeks in photoreceptor cell death was observed in the Ad.CMV beta PDE-treated group compared to controls.
- Evidence of cell rescue was demonstrated through the gene transfer approach.
Conclusions:
- In vivo gene transfer using Ad.CMV beta PDE can effectively rescue photoreceptor cells and delay degeneration.
- These findings provide strong support for the feasibility of using somatic gene therapy to treat inherited retinal degenerations.
- The study highlights a promising therapeutic strategy for genetic eye diseases.
